This quality initiative focuses on improving care pathways for patients with hormone receptor (HR)-positive/HER2-negative, node-positive early breast cancer at high risk of recurrence, addressing diagnostic optimization, treatment strategies, and long-term outcomes in real-world practice. Read More ›

The phase 2 AGAIN study examines abemaciclib rechallenge in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who have progressed on abemaciclib plus endocrine therapy, providing data on feasibility and outcomes. Read More ›

The VIKTORIA-1 trial evaluates gedatolisib with fulvestrant, with or without palbociclib, compared with fulvestrant alone in patients with hormone receptor (HR)-positive/HER2-negative/PIK3CA wild-type advanced breast cancer, offering early insights into treatment approaches. Read More ›

The OptiTROP-Breast02 trial examines sacituzumab tirumotecan versus investigator’s choice chemotherapy in previously treated hormone receptor (HR)-positive/HER2-negative advanced breast cancer, focusing on treatment strategies for this population. Read More ›

This real-world analysis investigates the relationship between ESR1-positivity rates and the length of exposure to endocrine therapy with or without cyclin-dependent kinase (CDK)4/6 inhibitors in hormone receptor (HR)-positive/HER2-negative breast cancer. Read More ›

This real-world study examines the role of ovarian function suppression as adjuvant therapy in hormone receptor (HR)-positive/HER2-positive premenopausal breast cancer patients who achieved pathologic complete response following neoadjuvant chemotherapy, analyzing its use within routine clinical practice. Read More ›

This study examines treatment duration and patterns of follow-up therapies after first-line cyclin-dependent kinase (CDK)4/6 inhibitor plus aromatase inhibitor use in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer in US clinical practice. Read More ›

Updated results from the monarchE trial indicate positive primary overall survival outcomes of adjuvant abemaciclib combined with endocrine therapy in hormone receptor (HR)-positive/HER2-negative high-risk early breast cancer. Read More ›

A preliminary analysis of the SOLTI-RIBOLARIS trial shows reduced recurrence risk in high-risk estrogen receptor (ER)-positive/HER2-negative breast cancer patients treated with neoadjuvant ribociclib and endocrine therapy, highlighting recurrence dynamics and potential clinical benefits. Read More ›

The POSITIVE trial’s 5-year follow-up reports favorable pregnancy outcomes and does not appear to increase the risk of breast cancer recurrence at 5 years in women with endocrine-responsive breast cancer. Read More ›